M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT

INTRODUCTION
Botulinum neurotoxins (BoNTs) are the most potent toxins known and are responsible for severe neurological disorder in man and animals. Botulism is acquired by ingestion of preformed BoNT in food (foodborne botulism), or after intestinal (infant botulism, adult intestinal toxemia botulism) or wound (wound botulism) colonization and in situ BoNT production [1] . Infant botulism occurs between two weeks and one year of age and results from ingestion of Clostridium botulinum spores or bacteria, subsequent clostridial growth and toxin production in the intestine, and finally passage of BoNT through the intestinal mucosa to motornerve endings. Infant botulism is common in some countries and certain states of the USA [1] [2] [3] but is rarely reported in Europe [4] .
In France, foodborne botulism is the main form of the disease whereas only a few cases of infant botulism have been identified [5] .
BoNTs are divided into seven toxinotypes (A to G) according to their immunological properties and in numerous subtypes based on amino acid sequence variations [6] . A new BoNT type called H has been reported but was characterized as an A/F hybrid [7, 8] . BoNTs are produced by heterogeneous groups of Clostridium including C. botulinum and atypical strains of other species such as Clostridium baratii and Clostridium butyricum [6] . Like other Clostridium species and anaerobes, C. botulinum is intrinsically resistant to aminoglycosides, to sulfamethoxazole and trimethoprim but remains susceptible to other drug classes [9, 10] . However, only a small number of strains have been tested for susceptibility to antibiotics [9, 10] . Antibiotics are frequently used for presumed sepsis [11, 12] . but might exacerbate botulinum symptoms [4, 11] . When indicated, β-lactams are the antibiotics of choice for clostridial infections [12] . We report the characterization, to the best of our knowledge, of the first C. botulinum strain resistant to β-lactams and responsible for an infant botulism case, M A N U S C R I P T
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MATERIALS AND METHODS
Ethics Statement
All experiments were performed in accordance with the French and European Community guidelines for laboratory animal handling (agreement of laboratory animal use n° 2013-0116).
DNA Preparation, Recombinant DNA Techniques, Protein Preparation
Total DNA was isolated from C. botulinum as described [13] . DNA extraction from stool samples was performed with DNA stool kit (Qiagen) according to the manufacturer's recommendations. Detection of C. botulinum in biological samples was performed by SYBR-green real-time PCR with specific primers as previously described [13] . The blaCBP gene was amplified with primers P2251 (GGATCCATGAAAAAAATAGTAAACTC) and P2252 (GTCGACTATTTCCTGGTGTTAATAAA) adding BamHI and SalI sites (underlined), and cloned into pET28a. The resulting plasmid introduced into E. coli BL21(DE3) was verified by DNA sequencing. The C. botulinum penicillinase (CBP) with a N-terminal 6-His tag was produced and purified as described [14] .
Toxin Detection
Toxin detection and titration in biological samples or in culture supernatants were performed by the mouse bioassay with specific neutralizing antibodies [15] . Half ml of ten-fold serial dilutions of samples in 50 mM phosphate buffer (pH 6.5) containing 1% gelatin were injected intraperitoneally into Swiss mice weighing 20-22 g (Charles River).
Whole Genome Sequencing (WGS)
The WGS libraries performed using the NEBNext Ultra DNA Library Prep kit for Illumina (New England Biolabs) were sequenced on MiSeq or HiSeq2000 machines (Illumina).
Sequence files were generated using Illumina Analysis Pipeline version 1.8 (CASAVA).
After quality filtering, reads were assembled using CLC software version 4 (CLC Bio).
RESULTS
Case Report
On February 21st 2013, a 2-month-old girl was hospitalized after 24 h of progressive Table S1 in the Supplementary Appendix) produced BoNT/A. Whole genome sequencing of these strains indicated that they were identical. The strains were assigned to subtype A2 based on the deduced amino acid sequences of bont/A genes and to the multi locus sequence typing (MLST) profile 22 [16] . Strain 224-13 was selected for further studies.
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In addition to C. botulinum intrinsic resistance to trimethoprim/sulfamethoxazole and aminoglycosides [17] the strain 224-13 was resistant to penicillin G, amoxicillin, ticarcillin, mezlocillin, and cephalothin but remained susceptible to other antibiotics including vancomycin (Table 1 ). The MICs against strain 224-13 confirmed high-level resistance (MIC >256 µg/mL) to penicillins and to cephalothin. Moreover, inducible, heterogeneous, and reversible resistance to metronidazole was observed in strain 224-13 as already described for C. difficile [18] . Colonies grew inside the inhibition zone after 48 h of incubation with MICs ranging from 1 to >256 µg/mL. It is noteworthy that albeit the agar disk diffusion method is not recommended by the CLSI (Clinical & Laboratory Standards Institute), the diffusion method with metronidazole disk (5 µg disk) allowed the detection of metronidazole heterogeneous resistance in C. difficile [18] as well as in C. botulinum (this study). A nim nitroimidazole reductase gene was found in the genome of 224-13 as in most C. botulinum group I strains which remain susceptible to the drug. However, this gene, when expressed, is responsible for high-level resistance to metronidazole and no typical promoter was found upstream indicating that it was not involved in heterogeneous resistance. Indeed, nim-independent metronidazole resistance has already been observed in other bacteria such as Bacteroides and C. difficile [18, 19] . Heterogeneous resistance to metronidazole might lead to recurrence or clinical failure as observed in C. difficile infections [20] .
C. botulinum 224-13 Contains a Functional β-lactamase Gene Cluster
Blast analysis of strain 224-13 genome revealed the presence of a gene for a putative β-lactamase related to that of Bacillus cereus (54% identity), Bacillus licheniformis (48%), and Staphylococcus aureus (40%) which was assigned to a novel family of class A enzymes designated CBP for C. botulinum penicillinase. Two genes related to the regulatory genes blaI and blaR1 in B. cereus and S. aureus [21] were found downstream M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 8 from blaP. In contrast to the cluster organization in these two species, in which the β-lactamase gene is transcribed in opposite direction to that of blaI and blaR1, the genes from strain 224-13 were in the same orientation. The base composition of the gene cluster was 27.5% similar to those of the chromosome of C. botulinum (mol% G+C 28%) and C. butyricum (29%).
The blaCBP gene cloned into E. coli conferred resistance to penicillins and susceptibility was restored by addition of β-lactamase inhibitors clavulanic acid and sulbactam ( Table 2 ). Benzylpenicillin was the best substrate for the enzyme with a high catalytic efficiency (kcat/Km, 2907 mM −1 s −1 ). CBP also hydrolyzed cephalothin with a catalytic efficiency 2.4-fold lower than that of benzylpenicillin, but was not active on ceftazidime and cefoxitin even at a high enzyme concentration (1 μM). Aztreonam was very weakly hydrolyzed and no activity was observed against imipenem (Table 3 ).
These data confirmed that blaCBP was responsible for β-lactam resistance in C. botulinum and were in agreement with the resistance phenotype.
The β-lactamase Gene Cluster is Present in Various C. botulinum Strains
In strain 224-13, the β-lactamase gene cluster was located in a 433 kb contig that also carried genes for ribosomal protein S5, and for RNA polymerase sigma factor indicating a chromosomal location. We did not find any known insertion sequence nor any prophage in the 200 kb vicinity of the cluster. Blast analysis of twenty complete genomes of C. botulinum in GenBank (last access, September 2015) with the blaCBP, blaI, and blaR1 sequences from 224-13 showed that C. botulinum Kyoto F [22] and H04402 065 [23] contained identical or closely related clusters (Table 4 and Figure S1 in the Supplementary Appendix). The cluster was also found in one additional strain with partially sequenced genome, C. botulinum F CDC54085. In addition, screening of a total of 62 genomes in our strain collection revealed that C. botulinum 301-13 responsible for M A N U S C R I P T
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9 foodborne botulism and 126-07 isolated from wound botulism also harbored the chromosomal cluster, and both isolates were resistant to penicillins (Table S2 in Whole genome sequencing of the C. botulinum isolates from the infant botulism case indicated the persistence of a single isolate and showed the presence of novel β-lactamase gene blaCBP and of downstream genes blaI, and blaR1 homologous to those of Bacillus spp. and S. aureus [21, 29] . Cloning of blaCBP from strain 224-13 into E. coli and kinetic of CBP (Table 3) confirmed that the gene is responsible for resistance to penicillins and that CBP belongs to a novel class A β-lactamase. Overall, kinetic parameters were in agreement with the resistance phenotype of the hosts indicating that, as with class A enzymes, penicillin G was the best substrate. However, the penicillinase activity was approximately 30-fold lower than that of TEM-1 class A β-lactamase, but similar to that of Streptomyces albus G serine β-lactamase [32]
The deduced sequences of blaCBP, blaI, and blaR1 were more closely related to those of the orthologues in C. butyricum than to those in B. cereus and to a lower extent in S. aureus (Table 4 ). This suggests that the genes could derive from a common ancestor with a distinct evolution in Clostridium and in other Gram-positive bacteria. This is further supported by the base composition of the C. botulinum bla gene cluster which is similar to that of Clostridium genomes and distinct from those of Bacillus and Staphylococcus. In neurotoxigenic C. butyricum, the β-lactamase gene was found to be In conclusion, we report an infant botulism case with prolonged excretion of a C. botulinum A2 strain resistant to penicillins and to low levels of metronidazole.
Antibiotics could be useful to eradicate C. botulinum from the intestine but are considered to be responsible for exacerbation of the symptoms [4, 11] . This observation stresses that, when antibiotics are indicated, susceptibility of C. botulinum should be investigated for appropriate therapy of patients with botulism. M A N U S C R I P T 
